Kestra Medical Technologies, Ltd. — Cyborg Score 7/10
Solid
Wearable Medical Devices / Digital Healthcare / Cardiovascular Medical Device
Strategic Profile
The flagship ASSURE WCD is a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest, accompanied by a suite of integrated digital solutions and services. Its integrated approach combining advanced monitoring, real-time therapeutic intervention, and comprehensive digital health support differentiates it in the competitive landscape of medical device technology.
Cyborg Score Rationale
FY2025 revenue reached $59.82 million, an increase of 115.05% year-over-year, demonstrating strong market traction in a high-growth segment. However, losses were -$126.14 million, 25.1% more than in 2024, indicating a pre-profitability stage with escalating burn rate. The company operates in an attractive market with analyst support but faces typical scale-up challenges.
Top Insights
Revenue doubled year-over-year in FY2025 to $59.82 million, demonstrating accelerating commercial adoption
6 analysts rate KMTS as "Buy" with 12-month price target of $28.67, implying 14.54% upside
Market capitalization of approximately $1.2B positions company as emerging player in $40B+ cardiovascular market
Company founded in 2014 by leaders from external (AED) and implantable (ICD) defibrillation industries, providing deep domain expertise
Named Competitors
CardioDiagnostics — Cardiac diagnostic and monitoring solutions
ICD Manufacturers — Traditional implantable defibrillator devices
Digital Cardiac Platforms — Connected cardiac monitoring and remote patient management
Recent Developments
(January 2026) Presented at 44th Annual J.P. Morgan Healthcare Conference